X4 Pharmaceuticals, Inc. (XFOR)
4.04
-0.19
(-4.49%)
USD |
NASDAQ |
Aug 28, 16:00
4.12
+0.08
(+1.98%)
After-Hours: 20:00
X4 Pharmaceuticals Cash from Operations (Quarterly) : -20.79M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.79M |
| March 31, 2026 | -19.60M |
| December 31, 2025 | -15.53M |
| September 30, 2025 | -27.82M |
| June 30, 2025 | -29.90M |
| March 31, 2025 | -12.37M |
| December 31, 2024 | -33.00M |
| September 30, 2024 | -34.03M |
| June 30, 2024 | -30.28M |
| March 31, 2024 | -33.60M |
| December 31, 2023 | -27.75M |
| September 30, 2023 | -20.83M |
| June 30, 2023 | -21.42M |
| March 31, 2023 | -26.51M |
| December 31, 2022 | -19.09M |
| September 30, 2022 | -19.31M |
| June 30, 2022 | -18.47M |
| March 31, 2022 | -20.23M |
| December 31, 2021 | -19.05M |
| September 30, 2021 | -14.21M |
| June 30, 2021 | -19.20M |
| Date | Value |
|---|---|
| March 31, 2021 | -18.44M |
| December 31, 2020 | -17.50M |
| September 30, 2020 | -14.33M |
| June 30, 2020 | -11.46M |
| March 31, 2020 | -15.53M |
| December 31, 2019 | -9.241M |
| September 30, 2019 | -12.77M |
| June 30, 2019 | -14.29M |
| March 31, 2019 | -11.75M |
| December 31, 2018 | -6.734M |
| September 30, 2018 | -6.721M |
| June 30, 2018 | -5.783M |
| March 31, 2018 | -6.182M |
| December 31, 2017 | -12.91M |
| September 30, 2017 | -5.09M |
| June 30, 2017 | -6.363M |
| March 31, 2017 | -3.511M |
| December 31, 2016 | -3.162M |
| September 30, 2016 | -18.48M |
| June 30, 2016 | 6.053M |
| March 31, 2016 | -6.053M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 197.07M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Anixa Biosciences, Inc. | -1.741M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.00M |
| Cash from Financing (Quarterly) | 0.075M |
| Free Cash Flow | -88.74M |
| Free Cash Flow Per Share (Quarterly) | -0.2041 |
| Free Cash Flow to Equity (Quarterly) | -25.76M |
| Free Cash Flow to Firm (Quarterly) | -23.62M |
| Free Cash Flow Yield | -21.62% |